Literature DB >> 17537735

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

Markey C McNutt1, Thomas A Lagace, Jay D Horton.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releases the prodomain at the N terminus of the protein. The prodomain remains tightly associated with the catalytic domain as the complex transits the secretory pathway. It is not known whether enzymatic activity is required for the LDLR-reducing effects of PCSK9. Here we expressed the prodomain together with a catalytically inactive protease domain in cells and purified the protein from the medium. The ability of the catalytically inactive PCSK9 to bind and degrade LDLRs when added to culture medium of human hepatoma HepG2 cells at physiological concentrations was similar to that seen using wild-type protein. Similarly, a catalytic-dead version of a gain-of-function mutant, PCSK9(D374Y), showed no loss of activity compared with a catalytically active counterpart; both proteins displayed approximately 10-fold increased activity in degradation of cell surface LDLRs compared with wild-type PCSK9. We conclude that the ability of PCSK9 to degrade LDLRs is independent of catalytic activity and suggest that PCSK9 functions as a chaperone to prevent LDLR recycling and/or to target LDLRs for lysosomal degradation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537735     DOI: 10.1074/jbc.C700095200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  95 in total

1.  Blackcurrant anthocyanins stimulated cholesterol transport via post-transcriptional induction of LDL receptor in Caco-2 cells.

Authors:  Bohkyung Kim; Minkyung Bae; Young-Ki Park; Hang Ma; Tao Yuan; Navindra P Seeram; Ji-Young Lee
Journal:  Eur J Nutr       Date:  2017-07-17       Impact factor: 5.614

2.  PCSK9 function and physiology.

Authors:  Andrew S Peterson; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-07       Impact factor: 5.922

3.  PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day.

Authors:  Yan Q Chen; Jason S Troutt; Robert J Konrad
Journal:  Lipids       Date:  2014-05       Impact factor: 1.880

4.  PCSK9 function and physiology.

Authors:  Andrew S Peterson; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-03-28       Impact factor: 5.922

Review 5.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

6.  PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway.

Authors:  Chun-Yan Wu; Zhi-Han Tang; Lu Jiang; Xue-Fei Li; Zhi-Sheng Jiang; Lu-Shan Liu
Journal:  Mol Cell Biochem       Date:  2011-08-17       Impact factor: 3.396

7.  Science, serendipity, and the single degree.

Authors:  Helen H Hobbs
Journal:  J Clin Invest       Date:  2018-10-01       Impact factor: 14.808

8.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

9.  PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

Authors:  Mary Cabell Jonas; Claudio Costantini; Luigi Puglielli
Journal:  EMBO Rep       Date:  2008-07-25       Impact factor: 8.807

10.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.